

Benedetto Maurizio Celesia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5707071/publications.pdf>

Version: 2024-02-01

59
papers

1,733
citations

471371

17
h-index

289141

40
g-index

60
all docs

60
docs citations

60
times ranked

2576
citing authors

#	ARTICLE	IF	CITATIONS
1	Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV. <i>Infectious Disease Reports</i> , 2022, 14, 43-55.	1.5	9
2	Parietal intrahemispheric source connectivity of resting-state electroencephalographic alpha rhythms is abnormal in Na ⁺ -HIV patients. <i>Brain Research Bulletin</i> , 2022, 181, 129-143.	1.4	1
3	HIV Infection Diagnosis in a Late Presenter Patient during a Severe Imported Falciparum Malaria: A Challenging. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 103-106.	0.1	1
4	Clinical characteristics and predictors of death among hospitalized patients infected with SARS-CoV-2 in Sicily, Italy: A retrospective observational study. <i>Biomedical Reports</i> , 2022, 16, 34.	0.9	16
5	Pulmonary Kaposi Sarcoma without Respiratory Symptoms and Skin Lesions in an HIV-Na ⁺ Patient: A Case Report and Literature Review. <i>Infectious Disease Reports</i> , 2022, 14, 228-242.	1.5	7
6	Reversibility of Central Nervous System Adverse Events in Course of Art. <i>Viruses</i> , 2022, 14, 1028.	1.5	8
7	Severe Neutropenia after Sarilumab Administration in Two COVID-19 Patients: Case Reports and Literature Review. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 142-147.	0.1	1
8	Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV. <i>Aids</i> , 2021, 35, 939-945.	1.0	19
9	Entecavir resistance in a patient with treatment-na ⁺ HBV: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 14, 113.	0.4	16
10	â€œDiagnosis on the Dockâ€•project: A proactive screening program for diagnosing pulmonary tuberculosis in disembarking refugees and new SEI model. <i>International Journal of Infectious Diseases</i> , 2021, 106, 98-104.	1.5	1
11	Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study. <i>AIDS Patient Care and STDs</i> , 2021, 35, 342-353.	1.1	15
12	Durability of Integrase STRand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPP0 cohort. <i>PLoS ONE</i> , 2021, 16, e0258533.	1.1	0
13	Postâ€•infectious ST elevation myocardial infarction following a COVIDâ€•19 infection: A case report. <i>Biomedical Reports</i> , 2021, 16, 10.	0.9	7
14	Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience. <i>Diagnostics</i> , 2021, 11, 2336.	1.3	15
15	<p>Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort</p>. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 2291-2300.	1.1	6
16	Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitorâ€•Based Regimen: The â€œSTOREâ€•Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 290-294.	0.9	3
17	Factors Associated With Weight Gain in People Treated With Dolutegravir. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa195.	0.4	47
18	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infectionâ€•Results of Italian Network of ACuTe HIV InfectiON (INACTiON) Retrospective Study. <i>Pathogens and Immunity</i> , 2020, 5, 8.	1.4	16

#	ARTICLE	IF	CITATIONS
19	<p>The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile</p>. Drug Design, Development and Therapy, 2020, Volume 14, 5515-5520.	2.0	24
20	Modification of Serum Brain-Derived Neurotrophic Factor Levels Following Anti-HCV Therapy with Direct Antiviral Agents: A New Marker of Neurocognitive Disorders. Hepatitis Monthly, 2020, 20, .	0.1	5
21	Successful Extracorporeal Membrane Oxygenation Treatment in an Acquired Immune Deficiency Syndrome (AIDS) Patient with Acute Respiratory Distress Syndrome (ARDS) Complicating Pneumocystis jirovecii Pneumonia: A Challenging Case. American Journal of Case Reports, 2020, 21, e919570.	0.3	20
22	Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPP0" Cohort. PLoS ONE, 2019, 14, e0222225.	1.1	9
23	<p>Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project</p>. Infection and Drug Resistance, 2019, Volume 12, 1385-1391.	1.1	19
24	Impact of genotypic susceptibility score on cART outcomes during primary HIV infection. Journal of Medical Virology, 2019, 91, 1891-1895.	2.5	0
25	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet, The, 2019, 393, 2428-2438.	6.3	627
26	IS IT SAFE AND COST SAVING TO DEFER THE CD4+ CELL COUNT MONITORING IN STABLE PATIENTS ON ART WITH MORE THAN 350 OR 500 CELLS/ÅµL?. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019063.	0.5	16
27	Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV subjects on cART: A potential marker of kidney disease. Biomedical Reports, 2019, 10, 140-144.	0.9	12
28	Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data. Annals of Pharmacotherapy, 2018, 52, 740-746.	0.9	36
29	Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. HIV Clinical Trials, 2018, 19, 242-248.	2.0	14
30	Therapy Adherence and Emotional Awareness and Regulation in Persons With Human Immunodeficiency Virus. Journal of Nervous and Mental Disease, 2018, 206, 925-930.	0.5	6
31	Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project. Infection and Drug Resistance, 2018, Volume 11, 615-623.	1.1	17
32	Cardiovascular risk in advanced na~ve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort. Atherosclerosis, 2017, 263, 398-404.	0.4	25
33	Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients. Journal of Hypertension, 2017, 35, 409-416.	0.3	21
34	Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, e76-e79.	0.7	7
35	Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. Aids, 2017, 31, 455-457.	1.0	47
36	Antiretroviral therapy in geriatric HIV patients: the GEPP0 cohort study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2879-2886.	1.3	30

#	ARTICLE	IF	CITATIONS
37	Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, 338-342.	0.9	9
38	Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. <i>PLoS ONE</i> , 2017, 12, e0179254.	1.1	17
39	PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection. <i>PLoS ONE</i> , 2017, 12, e0181433.	1.1	9
40	Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. <i>PLoS ONE</i> , 2017, 12, e0171611.	1.1	10
41	Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort. <i>PLoS ONE</i> , 2016, 11, e0164753.	1.1	41
42	Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study. <i>Infection</i> , 2016, 44, 589-597.	2.3	39
43	Effectiveness of first-generation HCV protease inhibitors. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 37-41.	0.8	2
44	Heel quantitative ultrasound in HIV-infected patients: a cross-sectional study. <i>Infection</i> , 2016, 44, 197-203.	2.3	5
45	Baseline CD4/CD8 T-Cell Ratio Predicts Prompt Immune Restoration Upon cART Initiation. <i>Current HIV Research</i> , 2016, 14, 491-496.	0.2	11
46	Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 289-294.	1.1	24
47	Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 7, 27.	0.7	5
48	HIV Genomic Mutations Causing Resistance to Antiretroviral Drugs in Seropositive Sicilians. <i>Current HIV Research</i> , 2014, 12, 32-43.	0.2	1
49	Decreasing cardiovascular risk in HIV infection between 2005 and 2011. <i>Aids</i> , 2014, 28, 609-612.	1.0	6
50	Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 189-194.	1.1	12
51	A measles outbreak in Catania, Sicily: the importance of high vaccination coverage and early notification of cases for health and economic reasons. <i>Infezioni in Medicina</i> , 2014, 22, 222-6.	0.7	5
52	Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project). <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 293-298.	2.5	16
53	Durability of Lopinavir/ritonavir mono-therapy in individuals with viral load ≥ 50 copies/mL in the observational setting. <i>Antiviral Therapy</i> , 2013, 19, 319-324.	0.6	5
54	Symmetric ambulatory arterial stiffness index and 24-h pulse pressure in HIV infection. <i>Journal of Hypertension</i> , 2013, 31, 560-567.	0.3	19

#	ARTICLE	IF	CITATIONS
55	Microbial Translocation in Chronic Liver Diseases. <i>International Journal of Microbiology</i> , 2012, 2012, 1-12.	0.9	86
56	Hepatic echinococcosis: Clinical and therapeutic aspects. <i>World Journal of Gastroenterology</i> , 2012, 18, 1448.	1.4	253
57	96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience. <i>PLoS ONE</i> , 2012, 7, e39222.	1.1	13
58	Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report. <i>Aids</i> , 2007, 21, 1495-1496.	1.0	11
59	Prevalence of HIV and Other Sexually Transmitted Diseases among Colombian and Dominican Female Sex Workers Living in Catania, Eastern Sicily. <i>Journal of Immigrant and Minority Health</i> , 2006, 8, 319-323.	0.8	8